세계의 항우울제 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Antidepressant Drugs Market reached USD 18.7 billion in 2024 and is projected to expand at a CAGR of 7.5% between 2025 and 2034. This growth is largely driven by the rising focus on mental health and the increasing need for effective treatments for depression and related disorders. Continuous advancements in pharmaceutical research have introduced innovative drugs targeting treatment-resistant depression, providing faster relief with improved tolerability. The availability of generic antidepressants has enhanced affordability, particularly in low- and middle-income regions, while telemedicine and online pharmacies have made mental health treatments more accessible to individuals in underserved areas.

Antidepressant drugs regulate neurotransmitters that influence mood, emotions, and behavior. The global market is segmented based on drug class, with selective serotonin reuptake inhibitors (SSRIs) holding a dominant 55.8% market share in 2024. Their widespread use is attributed to high efficacy, fewer side effects, and broad applicability in treating depression, anxiety, obsessive-compulsive disorder, panic disorder, and post-traumatic stress disorder. The availability of generic versions has further strengthened their market position by improving accessibility and affordability.

Based on application, the market is categorized into generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, panic disorder, and other conditions. The major depressive disorder segment led the market, reaching USD 9.5 billion in 2024. As awareness grows and the stigma around depression declines, more people seek medical assistance, leading to higher diagnosis rates and sustained demand for antidepressant medications. The necessity for long-term treatment further drives growth in this segment.

The market is divided by route of administration into oral, injectable, nasal, and transdermal formulations. The oral segment accounted for a significant portion of the market in 2024 and is projected to reach USD 30.2 billion by 2034. Tablets and capsules remain the preferred choice due to ease of administration, affordability, and established safety profiles. Both branded and generic oral antidepressants contribute to the segment's continued dominance by ensuring broad accessibility for patients.

Regarding medication type, the market is split into branded and generic drugs. The branded segment is expected to grow at a 7.2% CAGR during the forecast period, benefiting from strong marketing strategies, brand loyalty, and innovations aimed at treatment-resistant depression. Branded medications are often perceived as offering superior efficacy and safety, contributing to their increasing adoption.

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies held a 57.9% market share in 2024 due to the high volume of prescriptions for severe mental health conditions. These pharmacies offer specialized medications, ensuring better patient management through careful monitoring and treatment adjustments. A growing focus on specialized mental health services continues to support market expansion.

The U.S. antidepressant drugs market was valued at USD 6.8 billion in 2024. The high prevalence of mental health disorders, coupled with increasing awareness and a well-developed healthcare system, drives market growth. The accessibility of antidepressants through primary care physicians and mental health specialists ensures a steady rise in demand.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of depression and anxiety disorders
    • 3.2.1.2 Increasing investment in research and development
    • 3.2.1.3 Growing awareness regarding treatment therapies and mental health
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with some antidepressant drugs
    • 3.2.2.2 Customer preference for non-pharmacological therapeutics over pharmacological therapeutics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Selective serotonin reuptake inhibitors (SSRIs)
• 5.3 Serotonin and noradrenaline reuptake inhibitors (SNRIs)
• 5.4 Tricyclic antidepressants (TCAs)
• 5.5 Atypical antidepressants
• 5.6 Norepinephrine-dopamine reuptake inhibitor (NDRI)
• 5.7 Monoamine oxidase inhibitors (MAOIs)
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Major depressive disorder
• 6.3 Generalized anxiety disorder
• 6.4 Obsessive-compulsive disorder
• 6.5 Panic disorder
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Nasal
• 7.5 Transdermal

Chapter 8 Market Estimates and Forecast, By Medication Type, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Branded
• 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Bristol-Myers Squibb
• 11.2 Eli Lilly and Company
• 11.3 GlaxoSmithKline
• 11.4 Intra-Cellular Therapies
• 11.5 Janssen Pharmaceuticals
• 11.6 N.V. Organon
• 11.7 Novartis
• 11.8 Opko Health
• 11.9 Otsuka Pharmaceutical
• 11.10 Patheon
• 11.11 Pfizer
• 11.12 Sandoz
• 11.13 Sun Pharmaceuticals
• 11.14 Takeda Pharmaceuticals
• 11.15 Zhejiang NHU Company